Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fusion Antibodies Plc ( (GB:FAB) ) has issued an announcement.
Fusion Antibodies plc announced the upcoming commercial launch of its OptiMAL® Human Antibody Discovery platform, which integrates its Mammalian Display technology with the Opti-library to discover novel human antibodies. The technology boasts a high transduction efficiency of over 70% and supports large libraries exceeding 10⁹ variants, offering significant advantages over competitor platforms. This development positions Fusion Antibodies as a leader in the pre-clinical antibody discovery industry, potentially enhancing its market presence and stakeholder value.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £15.00 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc’s overall stock score is driven by positive technical indicators and promising corporate developments, particularly with the OptiMAL® platform. However, financial performance and valuation concerns due to ongoing profitability challenges and a negative P/E ratio weigh down the score.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Belfast-based contract research organization specializing in antibody engineering services for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company offers a wide range of services including antibody generation, development, production, characterization, and optimization. Fusion Antibodies has a strong international client base, including eight of the top 10 global pharmaceutical companies by revenue, and aims to accelerate drug development through innovative platforms and cutting-edge science.
Average Trading Volume: 1,036,862
Technical Sentiment Signal: Buy
Current Market Cap: £19.32M
Find detailed analytics on FAB stock on TipRanks’ Stock Analysis page.